Literature DB >> 8980144

The oligomerization domain of p53: crystal structure of the trigonal form.

M Miller1, J Lubkowski, J K Rao, A T Danishefsky, J G Omichinski, K Sakaguchi, H Sakamoto, E Appella, A M Gronenborn, G M Clore.   

Abstract

The structure of the oligomerization domain of the p53 tumor suppressor protein was determined in the trigonal crystal form, using a refined NMR structure as a model. A synthetic peptide comprising residues 319-360 of human p53 crystallized in the space group P3(1)21. There is one biologically relevant tetrameric domain in the crystallographic asymmetric unit. The structure was refined jointly with NMR data, only the third such case (the previous examples being IL-1beta (Shaanan, B., Gronenborn, A.M., Cohen, G.H., Gilliland, G.L., Veerapandian, B., Davies, D.R. and Clore, G.M. (1992) Science 257, 961-964 [1]) and BPTI (Schiffer, C., Huber, R., Wuthrich, K. and Van Gunsteren, W.F. (1994) J. Mol. Biol. 241, 588-599 [21)), to 2.5 A resolution with an R factor of 0.207. The distribution of tumor-derived mutations in the oligomerization region together with structural and biological data suggest a strategy for the design of antitumor therapeutics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980144     DOI: 10.1016/s0014-5793(96)01231-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes.

Authors:  A L Okorokov; J Milner
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Protein kinase CK2 interacts with a multi-protein binding domain of p53.

Authors:  C Götz; P Scholtes; A Prowald; N Schuster; W Nastainczyk; M Montenarh
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

3.  Joint refinement as a tool for thorough comparison between NMR and X-ray data and structures of HU protein.

Authors:  M L Raves; J F Doreleijer; H Vis; C E Vorgias; K S Wilson; R Kaptei
Journal:  J Biomol NMR       Date:  2001-11       Impact factor: 2.835

4.  Planck-Benzinger thermal work function: thermodynamic characterization of the carboxy-terminus of p53 peptide fragments.

Authors:  Paul W Chun; Marc S Lewis
Journal:  Protein J       Date:  2010-11       Impact factor: 2.371

5.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

6.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.

Authors:  M G Mateu; A R Fersht
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

Review 7.  The tumor suppressor p53: from structures to drug discovery.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02-10       Impact factor: 10.005

8.  p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma.

Authors:  Lucja Fiszer-Maliszewska; Bernarda Kazanowska; Joanna Padzik
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

9.  A fluid salt-bridging cluster and the stabilization of p53.

Authors:  Thu Zar Lwin; Jason J Durant; Donald Bashford
Journal:  J Mol Biol       Date:  2007-08-24       Impact factor: 5.469

10.  Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity.

Authors:  Valérie Lang; Chiara Pallara; Amaia Zabala; Sofia Lobato-Gil; Fernando Lopitz-Otsoa; Rosa Farrás; Roland Hjerpe; Monica Torres-Ramos; Lorea Zabaleta; Christine Blattner; Ronald T Hay; Rosa Barrio; Arkaitz Carracedo; Juan Fernandez-Recio; Manuel S Rodríguez; Fabienne Aillet
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.